MILESTONE PHARMACEUTICALS IN(NASDAQ:MIST) stock News

MIST Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals to Present at Upcoming Conferences

2 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

3 months ago - By: Benzinga - Mentions: WDFC AGM SGN TMDX ...

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

3 months ago - By: Benzinga - Mentions: CALC KPTI CAPR ATHE ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

3 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Proposed Public Offering

3 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

4 months ago - By: Zacks Investment Research

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

5 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

6 months ago - By: Yahoo Finance - Mentions: TSLA BLK

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

6 months ago - By: Yahoo Finance - Mentions: ICON LTRY APTO META ...

Icon Energy to effect 1-for-40 reverse stock split

6 months ago - By: Yahoo Finance - Mentions: APTO WGO BRZE IDXX ...

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

6 months ago - By: Yahoo Finance - Mentions: RJF WFC BRZE LVLU ...

Braze price target raised to $55 from $50 at Citi

6 months ago - By: Stocktwits - Mentions: GWX NVDA

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive

6 months ago - By: Milestone Pharmaceuticals Inc.

FDA Issues Complete Response Letter for Etripamil for PSVT

7 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

7 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

8 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

9 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 months ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

a year ago - By: Milestone Pharmaceuticals Inc.

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

a year ago - By: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

a year ago - By: Milestone Pharmaceuticals Inc.

MILESTONE PHARMACEUTICALS IN (MIST) Stock News

MIST Latest News, Press Relases and Analysis

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

12 Health Care Stocks Moving In Friday's Intraday Session

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

Icon Energy to effect 1-for-40 reverse stock split

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

Braze price target raised to $55 from $50 at Citi

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024